A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy

Table 1 Patient characteristics at baseline by treatment strategy (n = 1,373)

	Met/Incr	Met/SU	p-value vs. Met/Incr	Insulin ± any OAD	p-value vs. Met/Incr
	(n = 783)	(n = 324)	p-value vs. Met/Incr	(n = 266)	p-value vs. Met/Incr
Age (years)	64.0 (56.7–72.0)	67.5 (58.2–72.8)	0.026	62.6 (54.5–71.5)	0.074
Female gender (%)	47.6	46.9	0.83	42.1	0.12
Body weight (kg)	90.0 (79.0–103.0)	86.0 (78.0–98.5)	0.029	89.0 (78.0–100.0)	0.99
Diabetes duration (years)	4.6 (2.1–7.8)	5.2 (2.5–8.6)	0.079	6.6 (3.5–9.9)	<0.001
Blood glucose
HbA1c (%)	7.3 (6.8–7.9)	7.3 (6.8–8.1)	0.75	8.1 (7.3–9.5)	<0.001
FPG (mg/dl)	137 (118–164)	139 (117–162)	0.91	156 (132–205)	<0.001
PPG (mg/dl)	176 (147–211)	178 (158–215)	0.13	205 (174–241)	<0.001
Anamnestic hypoglycaemia* (%)	3.4	5.2	0.16	23.3	<0.001
Concomitant disease (%)
MACCE (%)	9.4	11.2	0.37	10.6	0.57
Macrovascular complication (%)	13.4	13.9	0.80	16.6	0.19
Microvascular complication (%)	14.7	12.4	0.31	22.9	0.002

Legend: Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG, fasting plasma glucose; PPG, postprandial plasma glucose; MACCE, major cardiac or cerebrovascular event; *within 12 months prior to baseline.

ISSN: 1475-2840